Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

REG - Benchmark Hlgs PLC - Market Authorisation Update

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC9826Ja&default-theme=true

RNS Number : 9826J  Benchmark Holdings PLC  03 May 2022

3 May 2022

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Ectosan® Vet

Variation to Marketing Authorisation enabling a second use of treatment water

An important milestone towards optimal efficiency of Benchmark's
transformational sea lice solution

 

Benchmark (LSE: BMK), the aquaculture biotechnology company, is pleased to
announce that it has been granted a variation to its Marketing Authorisation
("MA") for Ectosan® Vet  from the Norwegian Medicines Agency ("NoMA").

 

This variation to the MA enables the re-use of the treatment water for a
second batch of fish, subject to water quality being maintained to the
satisfaction of the prescribing veterinarian, therefore increasing the
efficiency of treatments. This means a producer will be able to treat a salmon
farm more efficiently with a solution that delivers more than 99% efficacy,
promotes animal welfare, reduces mortality and protects the environment -
driving sustainability in the industry.

 

This MA variation represents a further important step towards our goal of
optimising the efficiency of our sea lice solution, and further trials are
ongoing to support multiple re-use of treatment water.

 

 Trond Williksen, CEO, commented:

 

"We are very pleased to have been granted a variation to the Marketing
Authorisation from the Norwegian Medicines Agency. This represents an
important milestone for the Company and for the industry. Ectosan® Vet and
CleanTreat® is a much needed solution for the industry which continues to
show excellent results with efficacy above 99% as well as good operational
efficiency. It is the first medicinal solution brought to the Norwegian market
in over ten years which addresses one of the biggest challenges in salmon
production, while improving animal welfare, reducing mortality and protecting
the environment."

 

Enquiries:

 

 Benchmark Holdings plc                                       Tel: 020 3696 0630
 Trond Williksen, CEO

 Septima Maguire, CFO

 Ivonne Cantu, Investor Relations

 Numis (Broker and NOMAD)                                     Tel: 020 7260 1000
 James Black / Freddie Barnfield / Duncan Monteith

 MHP
 Katie Hunt/Charlie Protheroe/Fergal Bettridge-Boyd           Tel: 020 3128 8990

                                                              benchmark@mhpc.com (mailto:benchmark@mhpc.com)

About Benchmark

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses the major aquaculture species - salmon,
shrimp, sea bass and bream, and tilapia,  in all the aquaculture regions
around the world. Find out more at www.benchmarkplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBLLLBLELZBBL

Recent news on Benchmark Holdings

See all news